Cycloserine indications and usage: Difference between revisions
(Created page with "__NOTOC__ {{Cycloserine}} {{CMG}} ; {{AE}} {{chetan}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SEROMYCIN (CYCLOSERINE) CAPSULE [PURDUE GM...") |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} ; {{AE}} {{chetan}} | {{CMG}} ; {{AE}} {{chetan}} | ||
==INDICATIONS & USAGE== | |||
Seromycin is indicated in the treatment of active [[pulmonary]] and [[extrapulmonary tuberculosis]] (including renal disease) when the causative organisms are susceptible to this drug and when treatment with the primary medications (streptomycin, isoniazid, rifampin, and ethambutol) has proved inadequate. Like all antituberculosis drugs, Seromycin should be administered in conjunction with other effective chemotherapy and not as the sole therapeutic agent. | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SEROMYCIN (CYCLOSERINE) CAPSULE [PURDUE GMP CENTER LLC DBA THE CHAO CENTER] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e1e08327-4b90-463e-bb2a-22438cabcef2 | publisher = | date = | accessdate }}</ref> | Seromycin may be effective in the treatment of acute urinary tract infections caused by susceptible strains of gram–positive and gram–negative bacteria, especially Enterobacter spp. and Escherichia coli. It is generally no more and is usually less effective than other antimicrobial agents in the treatment of urinary tract infections caused by bacteria other than mycobacteria. Use of Seromycin in these infections should be considered only when more conventional therapy has failed and when the organism has been demonstrated to be susceptible to the drug.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SEROMYCIN (CYCLOSERINE) CAPSULE [PURDUE GMP CENTER LLC DBA THE CHAO CENTER] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e1e08327-4b90-463e-bb2a-22438cabcef2 | publisher = | date = | accessdate }}</ref> | ||
Revision as of 17:39, 26 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
INDICATIONS & USAGE
Seromycin is indicated in the treatment of active pulmonary and extrapulmonary tuberculosis (including renal disease) when the causative organisms are susceptible to this drug and when treatment with the primary medications (streptomycin, isoniazid, rifampin, and ethambutol) has proved inadequate. Like all antituberculosis drugs, Seromycin should be administered in conjunction with other effective chemotherapy and not as the sole therapeutic agent.
Seromycin may be effective in the treatment of acute urinary tract infections caused by susceptible strains of gram–positive and gram–negative bacteria, especially Enterobacter spp. and Escherichia coli. It is generally no more and is usually less effective than other antimicrobial agents in the treatment of urinary tract infections caused by bacteria other than mycobacteria. Use of Seromycin in these infections should be considered only when more conventional therapy has failed and when the organism has been demonstrated to be susceptible to the drug.[1]
References
- ↑ "SEROMYCIN (CYCLOSERINE) CAPSULE [PURDUE GMP CENTER LLC DBA THE CHAO CENTER]". Text " accessdate " ignored (help)
Adapted from the FDA Package Insert.